

Inhibition of glioma cell viability by jatrophone via NF- κ B down-regulation and apoptosis inhibitor up-regulation

Lei Yuan¹, Fei Wang², Ting Zhang², Yiming Zhang², Hong Pan², Guoguang Lv², Baozhong Zhang²

¹Postgraduate Training Base of Rocket Army Special Medical Center of Jinzhou Medical University, Jinzhou Medical University, Jinzhou, Liaoning, China

²Department of Neurosurgery, Rocket Army Medical Center, Beijing, China

Submitted: 2 January 2020

Accepted: 23 February 2020

Arch Med Sci

DOI: <https://doi.org/10.5114/aoms.2020.94439>

Copyright © 2020 Termedia © Banach

Corresponding author:

Dr Baozhong Zhang

Department of

Neurosurgery

Rocket Army

Medical Center

Beijing 100088, China

E-mail: sjwkbaozhong@sina.com

com

Abstract

Introduction: The present study evaluated the pro-survival signaling pathway inhibition potential of jatrophone in glioblastoma cells with the intention to develop effective treatment for glioblastoma.

Material and methods: Changes in proliferation of cells were measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Morphological changes were evaluated by electron microscopy and apoptosis by flow cytometry.

Results: The proliferative potential of glioma cells showed significant reduction on treatment with jatrophone. The shrinkage and detachment from the flask surface was prominent in glioma cells on treatment with 15 μ M jatrophone. Treatment with jatrophone (4.8 μ M) for 72 h increased apoptosis in U87MG and A172 cells. The immunocytochemistry showed a significant decrease in the level of intracellular NF- κ B p65 in glioma cells on treatment with jatrophone. Jatrophone treatment significantly suppressed nuclear NF- κ B p65/total NF- κ B p65 in glioma cells. Treatment with jatrophone suppressed levels of survivin, XIAP and Bcl-2 in glioma cells relative to control. The Bax level in glioma cells was enhanced markedly relative to control on treatment with jatrophone. Activation of caspase-9 and -3 in glioma cells was markedly increased on treatment with jatrophone.

Conclusions: Jatrophone acts as inhibitory agent for glioblastoma cell proliferation and mediator of apoptosis. Therefore, jatrophone can be used as a therapeutic agent for glioblastoma treatment.

Key words: glioblastoma, apoptosis, natural product, diterpenoid, anti-tumor.

Introduction

Glioblastoma multiforme ranks highest in cancer-related deaths caused by intracranial malignant diseases [1]. It alone accounts for more than 30% of all the primary tumors detected in human brain globally [1]. The studies have contributed significantly in understanding the genetic and cellular basics of glioblastoma multiforme but the poor prognosis has not been overcome to date [2]. The average survival of glioblastoma multiforme patients after diagnosis has been reported as only 2 years [3]. Gliomas of low grade gradually develop into high grade with varied kinetics depending on the patient [3]. Studies on glioblastoma multiforme

have led to development of novel treatment strategies such as the NovoTTF-100A system and therapeutic molecules such as temozolomide [4, 5]. These anti-glioblastoma treatment strategies are insufficient because inhibition of a single target is compensated by activation of another pro-survival signaling pathway [6]. Thus there is urgent need for a more effective chemotherapeutic strategy to target pro-survival and promote pro-apoptotic pathways for glioblastoma multiforme treatment.

Naturally occurring compounds have shown prominent chemotherapeutic and radio sensitizing activities for various types of diseases. Resveratrol, a phenolic compound present in red grapes, has potential to inhibit growth of different types of carcinoma cells such as brain, ovary and breast cancer cells [7–9]. Saponins isolated from *Ardisia pusilla* inhibit lung and glioblastoma cell growth via induction of apoptosis [10, 11]. These molecules target vital enzymes associated with pro-survival pathways such as phosphoinositide 3-kinase (PI3K)/Akt/mTOR and NF- κ B [12]. Moreover, the apoptosis inhibitors and members of the Bcl-2 anti-apoptotic protein family are also targeted by these chemotherapeutic compounds [12]. Jatrophone is a macrocyclic molecule consisting of diterpenoid structure with an oxaspiro core and many centers suitable for electrophilic attack [13–15]. The compound is present in *Jatropha isabelli* and *Jatropha gossypifolia* plants, which belong to the Euphorbiaceae family. Jatrophone was found to display anti-tumor, anti-malarial and anti-inflammatory activities [12–15]. The present study investigated the anti-glioblastoma potential of jatrophone (Figure 1) for U87MG and A172 glioma cells. The molecular mechanism associated with jatrophone-mediated inhibition of glioma cell growth was also explored.

Material and methods

Cell lines

The U87MG and A172 glioblastoma cells were purchased from the cell bank of the Fourth Military Medical University, China. The culture of cells was carried out in DMEM medium mixed with newborn




Figure 1. Chemical structure of jatrophone

calf serum (10%; Invitrogen) at 37°C in an incubator under humid atmosphere of 5% CO₂ and 95% air. After 24 h, serum free medium mixed with jatrophone was put into the plates. Primary astrocytes used in the study were gifted by Dr. Zhang from the Fourth Military Medicine University.

Cell proliferation assay

Changes in primary astrocyte, U87MG and A172 cell proliferation by jatrophone were measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The cells were treated with 1.25, 2.5, 3.75, 5, 7.5, 10, 12.5 and 15 μ M jatrophone in DMEM medium for 72 h at 37°C in an incubator. MTT solution with final concentration of 5 mg/ml was added to the plates and incubation was performed for 4 h. The medium was removed and 120 μ l of DMSO was put in each well of the plate. The formation of formazan crystals from MTT was measured by microplate reader (Bio-Rad Laboratories, Hercules, CA) at 485 nm wavelength.

Electron microscopy

Morphological changes in primary astrocytes, U87MG and A172 cells by jatrophone were detected by electron microscopy. The cells at 2.5×10^6 cells per cm² density in T-150 flasks were treated with 4.8 μ M jatrophone for 72 h. Trypsinization of cells with 0.25% trypsin was followed by centrifugation for 20 min at 1,200 xg. The cell pellets were subjected to fixing and subsequently embedded on cover slips. The 70-micron thin sections of cell layers were sliced using an ultramicrotome and stained using uranyl acetate and lead citrate dyes. The changes in morphology were detected under an electron microscope (JEM-2000EX, JEOL Ltd., Tokyo, Japan)

Hoechst 33342 staining

The apoptotic nuclear changes by jatrophone in primary astrocytes, U87MG and A172 cells were detected using Hoechst 33342 dyes. The cells put in 6-well plates at 2×10^6 cells per well distribution were treated with 4.8 μ M jatrophone for 72 h. The harvested cells after washing in PBS were subjected to fixing for 3 h in 70% ethyl alcohol at 4°C. Then cells were incubated for 5 min with Hoechst 33342 dye at 25°C, washed in PBS and visualized under a fluorescence microscope (Wetzlar, Germany) for apoptotic nuclear changes.

Annexin V/propidium iodide assay

The apoptotic cell fraction was subjected to semi-quantification by flow cytometry using Annexin V-FITC/PI Kit (Immunotech Co., Marseille,

France). The primary astrocytes, U87MG and A172 cells were distributed in 60-mm dishes at 1×10^5 cells per dish concentration and treated with 4.8 μ M jatrophone for 72 h. After harvesting, the cells were rinsed in PBS and then incubated for 20 min with Annexin-V (5 μ l) and PI (5 μ l) dyes (Sigma, St. Louis, MO) under darkness. The apoptotic cells were detected by flow cytometry and data analyzed using Modfit software (House, Inc., Topsham, ME).

Immunocytochemical analysis

The immune-reactive score for expression of nuclear NF- κ B p65 was evaluated using immunocytochemistry as previously reported [15]. Briefly, primary astrocytes, U87MG and A172 cells were treated with 4.8 μ M jatrophone. Following treatment, the cells were subjected to incubation with anti-NF- κ B p65 rat monoclonal antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) for 2 h and then with biotinylated rabbit anti-mouse IgG secondary antibodies.

Western blot analysis

Primary astrocytes, U87MG and A172 cells were treated with 4.8 μ M jatrophone for 72 h and the lysed in RIPA buffer (sodium chloride (150 mM), NP-40 (1%), sodium deoxycholate (0.5%), SDS (0.2%), tris-hydrochloride (50 mM at pH 8.0), EDTA (10 mM) and PMSF (1 mM; Sigma, Chemical, St. Louis, MO) for 45 min at 4°C. The lysate clarification was carried out by centrifugation at 14,000 xg for 25 min followed by determination of protein concentration using the BCA protein Assay Kit (Pierce, Rockford, IL). The equal protein quantities were resolved by electrophoresis on 12% SDS-PAGE and then transferred onto PVDF membranes (Millipore, MA, USA). Blocking of the membranes was performed by incubation at room temperature with TBS containing Tween-20 (0.1%) and 5% milk. Incubation with primary antibodies was carried out at 4°C overnight. Then PBS washed membranes were incubated for 2 h with HRP-con-

jugated anti-rabbit IgG secondary antibodies. Immunoreactive protein bands were subjected to visualization using an ECL Advance Detection kit (GE Healthcare Bio-Sciences, Tokyo, Japan). The following primary antibodies were used: anti-p65 (1 : 300, mouse monoclonal), anti-survivin (1 : 300, mouse monoclonal), anti-XIAP (1 : 300, mouse monoclonal), anti-Bax (1 : 600, rabbit polyclonal), anti-Bcl-2 (1 : 600, rabbit polyclonal), anti-cleaved caspase-9 (1 : 600, rabbit polyclonal), anti-cleaved caspase-3 p11 (1 : 600, rabbit polyclonal), and anti- β -actin (1 : 600, rabbit polyclonal).

Determination of nuclear NF- κ B

The fractionation of cellular lysate was performed using a Qproteome Nuclear Kit (Qiagen) to obtain the nuclear and cytosolic fractions in accordance with the manufacturer's instructions. The protein content in the fractions was quantified and then detected for NF- κ B level by western blotting using anti-p65 antibodies.

Statistical analysis

The data presented are mean \pm standard deviation (SD) of triplicate experiments. The data comparison was performed statistically by Student's *t*-test or one-way analysis of variance (ANOVA) followed by a Bonferroni multiple test. Analysis of the data was performed statistically using the SPSS 13.0 software. The level of *p* < 0.05 was taken to represent statistically significance differences.

Results

Suppression of U87MG and A172 cell viability by jatrophone

Cytotoxicity of jatrophone on U87MG and A172 cells was measured at 24 and 72 h on treatment with 1.25, 2.5, 3.75, 5.0, 7.5, 10, 12.5 and 15 μ M by MTT assay (Figure 2). The proliferative potential of U87MG and A172 cells was suppressed by jatrophone significantly depending on dose and treatment duration. Suppression of proliferation




Figure 2. Effect of jatrophone on proliferation of U87MG and A172 cells. The vehicle control and jatrophone-treated U87MG cells, A172 cells and primary astrocytes were assessed for proliferation changes by MTT assay

p* < 0.05, *p* < 0.02 and ****p* < 0.01 vs. vehicle control.

by jatrophone was slightly more prominent in A172 cells relative to U87MG cells. Treatment with jatrophone (15 μ M) suppressed U87MG and A172 cell proliferation to 38.7 ± 1.2 and $29.4 \pm 0.8\%$, respectively at 24 h. The IC₅₀ of jatrophone for U87MG and A172 cells at 24 h was 7.8 and 6.5 μ M, respectively. Jatrophone (15 μ M) treatment for 72 h suppressed proliferation of U87MG and A172 cells to 22.5 ± 0.8 (IC₅₀ 4.8 μ M) and $18.6 \pm 0.4\%$ (IC₅₀ 3.8 μ M), respectively. Moreover, jatrophone treatment for 72 h could not change the proliferation of primary astrocytes.

Jatrophone-induced apoptosis in U87MG and A172 cells

Treatment with jatrophone (4.8 μ M) for 72 h significantly induced apoptosis in U87MG and

A172 cells (Figure 3 A). The morphological features of jatrophone-treated U87MG and A172 cells showed apoptotic changes such as shrinking, cell detachment and aggregation. Apoptotic changes were not seen in the primary astrocytes treated with jatrophone for 72 h. Induction of apoptosis by jatrophone treatment in U87MG and A172 cells was also confirmed using Hoechst 33342 staining (Figure 3 B).

The jatrophone-induced apoptotic changes in U87MG and A172 cells were semi-quantified using AnnexinV/PI assay (Figures 4 A, B). Treatment with jatrophone (4.8 μ M) for 72 h increased apoptosis in U87MG and A172 cells to 49.5 ± 2.3 and $57.7 \pm 2.6\%$, respectively. The apoptotic fraction of vehicle control U87MG and A172 cells was 1.89 ± 0.2 and $2.87 \pm 0.4\%$, respectively.




Figure 3. Effect of jatrophone on U87MG and A172 cell apoptosis. The vehicle-control or jatrophone-treated cells were observed for apoptotic changes morphologically. **A** – The morphological changes in U87MG and A172 cells were observed using inverted microscopy. **B** – The nuclear apoptotic changes were detected using Hoechst 33342 staining by flow cytometry




Figure 4. Apoptosis analysis in U87MG and A172 cells by jatrophone using AnnexinV/PI assay. The vehicle-control or jatrophone-treated cells were observed for apoptosis by flow cytometry using AnnexinV/PI assay

P* < 0.05 and *p* < 0.02 vs. vehicle control.

Jatrophone caused cell cycle arrest in U87MG and A172 cells

In jatrophone (4.8 μ M) treated U87MG and A172 cells the G1/G0 phase cell population was significantly ($p < 0.05$) increased (Figure 5). Flow cytometry of jatrophone-treated U87MG and A172 cells showed a decrease in the S and G2/M phase cell population compared to control cells. This revealed that jatrophone arrests cell cycle in U87MG and A172 cells in G1/G0 phase.

Jatrophone reduced NF- κ B expression and its nuclear translocation

The intracellular NF- κ B p65 level in U87MG and A172 cells was suppressed significantly on treatment with jatrophone at 72 h (Figure 6 A). The intracellular NF- κ B p65 score in U87MG cells was decreased to 2.6 ± 0.4 on treatment with jatrophone compared to 8.9 ± 0.9 in vehicle control. Similarly, in A172 cells the score was decreased

to 1.9 ± 0.4 by jatrophone treatment relative to 8.0 ± 0.8 in the vehicle control. The score of nuclear to total NF- κ B p65 ratio in U87MG cells was suppressed by jatrophone from 61.2 ± 2.8 to $11.3 \pm 0.9\%$. In A172 cells the score of nuclear to total NF- κ B p65 ratio was reduced from 53.5 ± 2.7 to $9.5 \pm 0.7\%$ by jatrophone treatment (Figure 6 B).

Jatrophone suppressed IAPs

The expression of survivin and XIAP in U87MG and A172 cells was reduced markedly by jatrophone treatment at 4.8 μ M (Figure 7). The level of endogenous Bcl-2 was markedly higher and Bax expression very weak in U87MG and A172 cells. Treatment with jatrophone suppressed Bcl-2 and elevated Bax expression in U87MG and A172 cells. The Bcl-2/Bax ratio in U87MG and A172 cells was decreased by treatment with jatrophone. However, no change in Bcl-2/Bax ratio in U87MG and A172 cells was observed on treatment with jatrophone in primary astrocytes.




Figure 5. Jatrophone arrests U87MG and A172 cell cycle. The vehicle-control or jatrophone-treated cells were detected for cell cycle distribution by flow cytometry




Figure 6. Effect of jatrophone on NF-κB p65. The U87MG and A172 cells were treated with jatrophone or vehicle control for 72 followed by immunocytochemistry. Changes in intracellular NF-κB p65 score (A), nuclear to total NF-κB p65 ratio (B) in U87MG and A172 cells

* $P < 0.02$ vs. vehicle control.




Figure 7. Effect of jatrophone on NF-κB p65 and other proteins. The primary astrocytes, U87MG and A172 cells were treated with jatrophone or vehicle control and then assessed for expression of NF-κB p65, Bcl-2, Bax, survivin and XIAP by western blot assay

* $P < 0.05$ vs. vehicle control.

Jatrophone-induced activation of caspase-3 and caspase-9

The jatrophone-induced activation of caspase-9 and caspase-3 in primary astrocytes, U87MG and A172 cells was assessed by western blot assay (Figure 8). Treatment with jatrophone did not induce cleavage of caspase-3 and -9 in primary astrocytes. In U87MG and A172 cells caspase-3 and

-9 cleavage was promoted markedly by treatment with jatrophone.

Discussion

Glioblastoma resection is the most difficult and challenging surgery in neuro-oncology; therefore it is treated by surgery, radio and chemotherapies in combination. Various studies have been




Figure 8. Effect of jatrophone on caspase-9 and caspase-3. The primary astrocytes, U87MG and A172 cells were treated with jatrophone or vehicle control and then assessed for expression of cleaved caspase-9 and caspase-3 by western blot assay

* $P < 0.05$ and ** $P < 0.02$ vs. vehicle control.

conducted to understand the mechanism of neurological disorders to develop effective treatment strategies [16–19]. There has been some improvement in overall survival by temozolomide and irinotecan, but nearly half of the glioma patients are not benefitting due to cellular resistance [20]. The present study showed that jatrophone exhibits an anti-proliferative effect on U87MG and A172 glioma cells by inducing apoptosis and inhibition of NF- κ B expression. Jatrophone showed no inhibitory effect on proliferation of primary astrocytes, which comprise a major portion of the brain parenchyma. In glioblastoma cells the proteins of the NF- κ B pathway are activated constitutively as a genetic feature [21]. The NF- κ B has a key role as a mediator for various survival signaling pathways which regulate activation of genes associated with cellular survival and growth [22]. In glioblastoma cells NF- κ B present in the nucleus has a major role in maintaining the malignant phenotype of cells [23]. It is reported that NF- κ B expression impacts average survival of glioma patients and it is believed to be an unfavorable factor for prognosis [24]. NF- κ B inhibition by bortezomib has been found to improve the anti-tumor activity of docetaxel for glioma cells by preventing chemoresistance [25]. In the present study jatrophone suppressed U87MG and A172 glioma cell viability specifically without any toxicity for primary astrocytes. The jatrophone-induced anti-proliferative effect for U87MG and A172 cells was associated with activation of apoptosis. The data from

western blotting demonstrated that jatrophone down-regulated expression of NF- κ B in U87MG and A172 cells. This suggested that jatrophone exhibited an anti-proliferative effect on glioma cells by targeting NF- κ B expression, which is involved in cell viability. Apoptosis inhibitors, survivin and XIAP are components of the pro-survival pathway which counter pro-apoptotic signals induced by chemotherapeutic molecules [26]. Studies have found that targeting these apoptosis inhibitors leads to death of some glioma cells [27, 28]. Studies on glioblastoma specimens have demonstrated that the poor average survival of glioma patients is probably related to over-expression of survivin [29]. It is reported that expression of survivin shows gradual enhancement with the increase in pathological grade of glioma [30]. The spontaneous induction of apoptosis has been found to be inversely related to the expression of survivin in glioblastoma cells, which highlights its role as a target for treatment strategies [31]. The survivin protein is believed to be linked with the chemoresistance of not only glioblastomas but also various other cancer cells [32]. The present study showed that survivin and XIAP expression in U87MG and A172 cells is suppressed by jatrophone. These findings indicate that jatrophone eliminates chemoresistance of U87MG and A172 cells by targeting survivin and XIAP. Inhibition of survivin can lead to apoptosis by promotion of Bax and inhibition of Bcl-2 proteins [33]. The data from the present study confirmed that jatrophone

decrease increased Bax and suppressed Bcl-2 expression in U87MG and A172 cells.

In conclusion, jatrophone inhibits cellular growth by inducing apoptosis in U87MG and A172 glioblastoma cells. The anti-glioblastoma potential of jatrophone is associated with suppression of NF- κ B expression, targeting apoptosis inhibitors and promotion of pro-apoptotic proteins. Thus, jatrophone has potential to inhibit glioblastoma and therefore may be used to develop anti-glioblastoma treatment.

Conflict of interest

The authors declare no conflict of interest.

References

1. Preusser M, de Ribaupierre S, Wöhrer A, et al. Current concepts and management of glioblastoma. *Ann Neurol* 2011; 70: 9-21.
2. Dunn GP, Rinne ML, Wykosky J, et al. Emerging insights into the molecular and cellular basis of glioblastoma. *Genes Dev* 2012; 26: 756-84.
3. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med* 2005; 352: 987-96.
4. Stupp R, Weller M. Neuro-oncology is moving! *Curr Opin Neurol* 2010; 23: 553-5.
5. Dorefsky AS, King JT Jr, Dubrow R. Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of surveillance, epidemiology, and end results registries. *Cancer* 2012; 118: 2163-72.
6. Hegi ME, Janzer RC, Lambiv WL, et al. Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE3 trial. *Acta Neuropathol* 2012; 123: 841-52.
7. Kisková T, Ekmekcioglu C, Garajová M, et al. A combination of resveratrol and melatonin exerts chemopreventive effects in N-methyl-N-nitrosourea-induced rat mammary carcinogenesis. *Eur J Cancer Prev* 2012; 21: 163-70.
8. Lee MH, Choi BY, Kundu JK, et al. Resveratrol suppresses growth of human ovarian cancer cells in culture and in a murine xenograft model: eukaryotic elongation factor 1A2 as a potential target. *Cancer Res* 2009; 69: 7449-58.
9. Filippi-Chiela EC, Villodre ES, Zamin LL, Lenz G. Autophagy interplay with apoptosis and cell cycle regulation in the growth inhibiting effect of resveratrol in glioma cells. *PLoS One* 2011; 6: e20849.
10. Xiong J, Cheng G, Tang H, Zhen HN, Zhang X. Ardipusilloside I induces apoptosis in human glioblastoma cells through a caspase-8independent FasL/Fas-signaling pathway. *Environ Toxicol Pharmacol* 2009; 27: 264-70.
11. Lin H, Zhang X, Cheng G, et al. Apoptosis induced by ardipusilloside III through BAD dephosphorylation and cleavage in human glioblastoma U251MG cells. *Apoptosis* 2008; 13: 247-57.
12. Jiang H, Shang X, Wu H, et al. Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma cells. *J Exp Ther Oncol* 2009; 8: 25-33.
13. Devappa RK, Makkar HP, Becker K. Nutritional, biochemical, and pharmaceutical potential of proteins and peptides from jatropha: review. *J Agric Food Chem* 2010; 58: 6543-55.
14. Lillo MA, Nichols C, Perry C, et al. Methylparaben stimulates tumor initiating cells in ER+ breast cancer models. *J Appl Toxicol* 2017; 37: 417-25.
15. Vidal G, Bursac Z, Miranda-Carboni G, White-Means S, Starlard-Davenport A. Racial disparities in survival outcomes by breast tumor subtype among African American women in Memphis, Tennessee. *Cancer Med* 2017; 6: 1776-86.
16. Meryem KE, Gulcin SE, Ecmel IK, et al. Etanercept protects ovarian reserve against ischemia/reperfusion injury in a rat model. *Arch Med Sci* 2019; 15: 1104-12.
17. Haixia G, Yuelin H, Chaoke B, Zhiyong P. Antitumor and apoptotic effects of 5-methoxypsoralen in U87MG human glioma cells and its effect on cell cycle, autophagy and PI3K/Akt signaling pathway. *Arch Med Sci* 2019; 15: 1530-8.
18. Zichuan W, Nan C, Jin Y, Qingzhong W, Aimin L. Microarray gene profiling analysis of glioblastoma cell line U87 reveals suppression of the FANCD2/Fanconi anemia pathway by the combination of Y15 and temozolomide. *Arch Med Sci* 2019; 15: 1035-46.
19. Long Y, Lu J, Dongdong J, Baiying L, Shi J. The protective effects of salvianolic acid A against hepatic ischemia-reperfusion injury via inhibiting expression of toll-like receptor 4 in rats. *Arch Med Sci* 2019; 15: 1599-607.
20. Motomura K, Natsume A, Kishida Y, et al. Benefits of interferon-beta and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: a multicenter study. *Cancer* 2011; 117: 1721-30.
21. Nogueira L, Ruiz-Ontañón P, Vazquez-Barquero A, Moris F, Fernandez-Luna JL. The NF κ B pathway: a therapeutic target in glioblastoma. *Oncotarget* 2011; 2: 646-53.
22. Smith D, Shimamura T, Barbera S, Bejcek BE. NF- κ B controls growth of glioblastomas/astrocytomas. *Mol Cell Biochem* 2008; 307: 141-7.
23. Zhao X, Laver T, Hong SW, et al. An NF κ B p65-cIAP2 link is necessary for mediating resistance to TNF α induced cell death in gliomas. *J Neurooncol* 2011; 102: 367-81.
24. Guo K, Kang NX, Li Y, et al. Regulation of HSP27 on NF- κ B pathway activation may be involved in metastatic hepatocellular carcinoma cells apoptosis. *BMC Cancer* 2009; 9: 100.
25. Chung CH, Aulino J, Muldowney NJ, et al. Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. *Ann Oncol* 2010; 21: 864-70.
26. Pavlyukov MS, Antipova NV, Balashova MV, et al. Survivin monomer plays an essential role in apoptosis regulation. *J Biol Chem* 2011; 286: 23296-307.
27. Zanutto-Filho A, Braganhol E, Schröder R, et al. NF κ B inhibitors induce cell death in glioblastomas. *Biochem Pharmacol* 2011; 81: 412-24.
28. George J, Banik NL, Ray SK. Survivin knockdown and concurrent 4-HPR treatment controlled human glioblastoma in vitro and in vivo. *Neuro Oncol* 2010; 12: 1088-101.
29. Kogiku M, Ohsawa I, Matsumoto K, et al. Prognosis of glioma patients by combined immunostaining for survivin, Ki-67 and epidermal growth factor receptor. *J Clin Neurosci* 2008; 15: 1198-203.
30. Angileri FF, Aguenouz M, Conti A, et al. Nuclear factor-kappaB activation and differential expression of

- survivin and Bcl-2 in human grade 2-4 astrocytomas. *Cancer* 2008; 112: 2258-66.
31. Zhen HN, Zhang X, Hu PZ, et al. Survivin expression and its relation with proliferation, apoptosis, and angiogenesis in brain gliomas. *Cancer* 2005; 105: 2775-83.
 32. Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. *Clin Cancer Res* 2008; 14: 5000-5.
 33. Chen XQ, Yang S, Li ZY, et al. Effects and mechanism of downregulation of survivin expression by RNA interference on proliferation and apoptosis of lung cancer cells. *Mol Med Report* 2012; 5: 917-22.